Mr. Guinan has served as a member of our board since September 2018. Since July 2013, Mr. Guinan has served as the Executive Vice President and Chief Financial Officer at Quest Diagnostics Incorporated, a provider of diagnostic information services. From 2010 to 2013, he served as Chief Financial Officer for Hill-Rom Holdings Inc., a manufacturer and provider of medical technologies and related services for the health care industry. Previously, he served in a number of finance and operations roles in a long career at Johnson & Johnson including as Vice President, Chief Procurement Officer, and as the CFO of the pharmaceutical business. Before joining Johnson & Johnson in 1997, Mr. Guinan held a number of financial roles at Procter & Gamble. He received his BA in economics from the University of Notre Dame and his MBA from Olin Business School at the Washington University in St. Louis.

Ms. Gulfo has served as a member of our board since December 2019. Since December 2019, Ms. Gulfo has served as the Chief Business and Commercial Development Officer at Sumitovant Biopharma. From May 2018 to December 2019, Ms. Gulfo served as Chief of Commercial Development at Roivant Sciences. Previously, she was Chief Strategy Officer, Executive Vice President, and Head of Global Commercial Development at Mylan. She also served in a number of executive leadership roles at Pfizer, including President and General Manager of the U.S. primary care business and President of Latin America. In addition to serving on our board, Ms. Gulfo also currently serves on the boards of EnPro Industries and Medexus Pharma. Ms. Gulfo received a BS from Seton Hall University and a MBA from Fairleigh Dickinson University.

Mr. Marek has served as our Chief Executive Officer and a member of our board since January 2021. Mr. Marek is the Principal Executive Officer of Myovant Sciences Ltd. and the Chief Executive Officer of Myovant Sciences, Inc. Previously, Mr. Marek served on the Executive Committee and as the Chief Commercial Officer of Axsome Therapeutics, where he led the buildout of commercial capabilities in preparation for expected product launches. Mr. Marek previously served as Vice President and General Manager of Amgen’s Neuroscience business unit, and as Vice President of Marketing of Amgen’s U.S. Inflammation and Nephrology busines units. At Amgen, Mr. Marek led the U.S. commercialization strategy and launch of Aimovig® (erenumab-aooe) for migraine prevention. Before Amgen, Mr. Marek served as Executive Vice President, Consumer Services, and Commercial Strategy Officer of WebMD, and as Managing Director of Saatchi & Saatchi Healthcare Advertising. Mr. Marek began his career at Eli Lilly and Company, followed by AstraZeneca, where he served in a variety of marketing and sales roles of increasing responsibility. He earned a BA in business administration from Washington State University.

Mr. Nomura has served as a member of our board since December 2019. Since April 2018, Mr. Nomura has been President, CEO, and Representative Director of Sumitomo Dainippon Pharma. Prior to his current role, Mr. Nomura served in a number of executive leadership roles at Sumitomo Dainippon Pharma, including Board of Directors, Senior Executive Officer, and Chief Finance Officer. He also served on the Board of Directors and as Vice Chairman, Executive Vice President, and Chief Financial Officer of Sunovion Pharmaceuticals. Mr. Nomura received a Bachelor of economics from University of Tokyo. 

Ms. Potter has served as a member of our board since September 2018. Since December 2019, Ms. Potter has served as the Chief Executive Officer of Sumitovant Biopharma. From July 2018 to December 2019, Ms. Potter served as Vant Operating Chair for Roivant Pharma, a division of Roivant Sciences. Ms. Potter founded Myrtle Potter & Company, LLC, a private healthcare and life sciences consulting firm in 2005 and served as the Chief Executive Officer until she joined Roivant. She previously served as President of Commercial Operations and Executive Vice President, and Chief Operating Officer of Genentech. Prior to Genentech, she held various positions, including President of Cardiovascular/Metabolics at Bristol-Myers Squibb. She is a graduate of the University of Chicago. In addition to serving on our board, Ms. Potter also serves on the boards of Liberty Mutual Holdings Company and Axsome Therapeutics. Ms. Potter also previously served on the boards of Amazon, Express Scripts, Medco Health Solutions, and Rite Aid.

Ms. Sebelius has served as a member of our board since October 2016. From April 2009 to June 2014, Ms. Sebelius served as U.S. Secretary of Health and Human Services (HHS). As Secretary of HHS, she presided over 11 operating divisions, including the CDC, FDA, and NIH and oversaw the passage and implementation of the Affordable Care Act. Before joining President Obama’s cabinet, Ms. Sebelius served as Governor of Kansas, elected in 2002 and re-elected in 2006. She had previously been elected twice as the Kansas Insurance Commissioner and from 1987 to 1995 served in the Kansas House of Representatives. Ms. Sebelius also currently serves as a director of Dermira Inc., a medical dermatology company, and Exact Sciences Inc., a cancer diagnostics company. She is a trustee of the Kaiser Family Foundation and co-chairs the Health Strategy Group for the Aspen Institute. Ms. Sebelius received a BA in political science from Trinity Washington University and a Master of Public Administration from the University of Kansas.